Biogen Idec (BIIB)
Biogen Idec Market Cap: 31.41B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BIIB Market Cap Rankings
| Overall | 96th percentile | 156 of 4649 |
| Sector | 96th percentile | 17 of 525 in Healthcare |
| Industry | 98th percentile | 3 of 163 in Biotechnology |
BIIB Market Cap Range, Past 5 Years
| Minimum | 12.67B | Jun 2010 |
| Maximum | 31.41B | May 25 2012 |
| Average | 18.47B |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these BIIB related companies
BIIB News
Wondering Which Stocks to Sell? There’s a List and We Explain How to Read It http://stks.co/3ysW $NFLX $PCS $EA $BIIB $CBS $COG $DF
about 3 days ago by ycharts
about 3 days ago by ycharts
$BIIB http://stks.co/3tiV Daily CCI diveregence and reached target today under 20sma daily support http://stks.co/3tiW
about 10 days ago by xpertstocktrader
about 10 days ago by xpertstocktrader
New Analysis of Risk Stratification for TYSABRI® Published in New England Journal of Medicine
May 17, 3:40PM Business Wire
May 17, 3:40PM Business Wire
$BIIB http://stks.co/3sIv partials at 10sma daily support and rest to entry price. http://stks.co/3sIw
about 11 days ago by xpertstocktrader
about 11 days ago by xpertstocktrader
$BIIB http://stks.co/3sD3 BIIB short under 136.10, stop above 138. Swing ods and good for 50% risk http://stks.co/3sD4
about 11 days ago by xpertstocktrader
about 11 days ago by xpertstocktrader
$BIIB http://stks.co/3s58 Idea is to watch CCI divergence and initial move down http://stks.co/3s59
about 11 days ago by xpertstocktrader
about 11 days ago by xpertstocktrader
RT @upsidetrader NEW POST: IS BIG BIOTECH READY TO FAIL? http://stks.co/3rgZ $IBB $CELG $SPX, $QQQ $BIIB $ALXN
about 11 days ago by packerfan48051
about 11 days ago by packerfan48051
NEW POST: IS BIG BIOTECH READY TO FAIL? http://stks.co/3reR $IBB $CELG $SPX, $QQQ $BIIB $ALXN
about 11 days ago by upsidetrader
about 11 days ago by upsidetrader
RT@Fibline $BIIB think thats a piece of $FBT- and $IBB@gregharmon mentioned yesterday. Report back tom
about 12 days ago by CaptainJohn
about 12 days ago by CaptainJohn
$BIIB http://stks.co/3qT9 Cont.'s to act well & orderly. Would not chase here. If it gets a pullback worth a try. Nice volume.
about 12 days ago by Fibline
about 12 days ago by Fibline
$MDVN $ARNA $ARIA $BIIB Noticed a bunch of pharma setting up over the weekend. I see why now.
about 14 days ago by Fibline
about 14 days ago by Fibline
$BIIB http://stks.co/3oWF Odds for new high and run to $140 target area - http://stks.co/3oWG
about 14 days ago by xpertstocktrader
about 14 days ago by xpertstocktrader
New AVONEX® Dosing Innovations for People with Multiple Sclerosis Now Available in US
May 14, 8:00AM Business Wire
May 14, 8:00AM Business Wire
RT@Fibline Excellant! or if chicken $FBT has litle over 5% of $BIIB both look great #drugs #getinmybelly :>)
about 15 days ago by CaptainJohn
about 15 days ago by CaptainJohn
$BIIB http://stks.co/3nbt "Stairsteps to Promise Land" or "Biotech Hand Grenade?". Like this set up.
about 15 days ago by Fibline
about 15 days ago by Fibline
$BIIB http://stks.co/3n5z BIIB at 137.50 resistance area..good for partials and rest for $140 http://stks.co/3n60
about 17 days ago by xpertstocktrader
about 17 days ago by xpertstocktrader
Goldman Sachs Said Biogen's (BIIB) BG-12 Acceptance Should Alliaate Concerns
May 10, 12:26PM Street Insider
May 10, 12:26PM Street Insider
US and EU Regulatory Authorities Accept Oral BG-12 Marketing Applications for Review
May 09, 4:05PM Business Wire
May 09, 4:05PM Business Wire
UBS Maintains a 'Buy' on Biogen (BIIB); Core Franchise Support Valuation; Pipeline Provides Upside Risk
May 09, 12:38PM Street Insider
May 09, 12:38PM Street Insider
Biogen Idec to Present at the Deutsche Bank 37th Annual Healthcare Conference
May 02, 5:22PM Business Wire
May 02, 5:22PM Business Wire
Goldman Sachs Maintains Bullish Stance on Biogen (BIIB), Sees Room for Significant Upside
May 02, 7:55AM Street Insider
May 02, 7:55AM Street Insider
Baird Maintains a 'Neutral' on Biogen (BIIB); Still Prefer the Sidelines as Pipeline Remains The Focus
May 01, 3:58PM Street Insider
May 01, 3:58PM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BIIB | 131.56 | -0.09 | -0.07% | 31.41B |
| BIG | 37.30 | +1.55 | +4.34% | 2.469B |
| BIF | 5.73 | +0.01 | +0.17% | |
| BIDZ | 0.76 | +0.01 | +0.66% | 13.97M |
| BDN | 11.29 | -0.07 | -0.62% | 1.611B |
| BDMS | 16.95 | -0.04 | -0.23% | 31.19M |
| BDL | 7.30 | +0.11 | +1.53% | 13.58M |
| BDJ | 7.16 | +0.02 | +0.28% | |
| BDGE | 19.78 | +0.00 | +0.00% | 167.54M |
| BDE | 9.14 | +0.09 | +0.99% | 280.42M |
